University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Swallowing Impairment After COVID-19 Infection

Completed

Conditions: Covid19

Interventions: Diagnostic Test: Videofluoroscopic Swallowing Study (VFSS)

First Posted Date: 2020-09-03

Last Posted Date: 2023-12-06

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 44

Registration Number: NCT04537650

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇺🇸
University of Florida, Gainesville, Florida, United States

Deoxyhemoglobin Concentration Changes and Cerebral Perfusion Imaging

Not Applicable

Conditions: Neurovascular Disorder
Stenosis, Carotid
Stroke

Interventions: Diagnostic Test: dHb contrast and gadolinium contrast imaging

First Posted Date: 2020-09-03

Last Posted Date: 2021-04-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 25

Registration Number: NCT04537611

Locations: 🇨🇦
Joseph Fisher, Toronto, Ontario, Canada

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

Phase 2

Recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Empagliflozin 25 MG + Liraglutide 1.8 MG
Drug: Liraglutide 1.8 MG + Empagliflozin 25 MG

First Posted Date: 2020-09-02

Last Posted Date: 2023-05-17

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 36

Registration Number: NCT04535960

Locations: 🇨🇦
Renal Physiology Laboratory, Toronto, Ontario, Canada

Ex-Vivo COF Study for Lung Cancer Observation

Recruiting

Conditions: Lung Cancer

First Posted Date: 2020-09-01

Last Posted Date: 2024-12-04

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT04534413

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Factor In the Initial Resuscitation of Severe Trauma 2 Patients

Phase 4

Recruiting

Conditions: Traumatic Hemorrhage
Coagulopathy
Massive Hemorrhage

Interventions: Biological: Frozen Plasma
Biological: Fibrinogen + PCC

First Posted Date: 2020-09-01

Last Posted Date: 2022-12-05

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 350

Registration Number: NCT04534751

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦
Hamilton Health Sciences and McMaster University, Hamitlon, Ontario, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

and more 3 locations

Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)

Conditions: Pain
Sleep
Epilepsy
Depression
Anxiety

First Posted Date: 2020-08-25

Last Posted Date: 2022-04-11

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 2000

Registration Number: NCT04526093

Locations: 🇨🇦
Toronto General Hospital, UHN, Toronto, Ontario, Canada

Partial Neuromuscular Blockade in Acute Respiratory Distress Syndrome

Not Applicable

Terminated

Conditions: Respiratory Insufficiency
Extracorporeal Membrane Oxygenation Complication
Neuromuscular Blockade

Interventions: Drug: Neuromuscular blockade

First Posted Date: 2020-08-24

Last Posted Date: 2024-12-11

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 4

Registration Number: NCT04524585

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Refractory Cancer
Classical Hodgkin Lymphoma
Relapsed Cancer

Interventions: Drug: Pembrolizumab
Drug: Bendamustine Hydrochloride

First Posted Date: 2020-08-12

Last Posted Date: 2024-03-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 37

Registration Number: NCT04510636

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Phase 2

Withdrawn

Conditions: Ovarian Endometrioid Tumor
TP53 Mutation
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2020-08-12

Last Posted Date: 2023-06-06

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT04510584

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

The Person-centered Evolution of Radiotherapy Services in Ontario Study

Not Applicable

Active, not recruiting

Conditions: Quality of Life
Breast Cancer

Interventions: Other: Quality of Life Questionnaires

First Posted Date: 2020-08-11

Last Posted Date: 2023-10-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 109

Registration Number: NCT04507568

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy